Adagio Therapeutics (NSDQ:ADGI) saw its share price drop 82% to $6.85 in afternoon trading after releasing data reflecting a reduction in vitro neutralizing activity of ADG20 against the Omicron SARS-CoV-2 variant.  ADG20, the company’s lead product candidate, is a neutralizing monoclonal antibody intended to potentially treat and prevent COVID-19.  In vitro data from authentic and…